TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9394582

Group type: EXPERIMENTAL
Intervention: Aspirin discontinued two days before operation (Group I)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aspirin continued up to operation (Group II)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no aspirin for at least seven days before operation)
Number of subjects: 22
Study: 7965266

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 3678266

Group type: EXPERIMENTAL
Intervention: Propafenone (450 mg to 900 mg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29082595

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (25 ml beetroot juice, one shot per day for 3 days)
Number of subjects: 7
Study: 27207917

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 0
Study: 25153949

Group type: EXPERIMENTAL
Intervention: 14-session positive psychology group intervention (n = 87)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Wait list group (n = 88)
Number of subjects: 175
Study: 22578685

Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 125
Study: 19947907

Group type: EXPERIMENTAL
Intervention: SC ceftriaxone with rHuPH20 (350 mg/mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: SC ceftriaxone preceded by placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: IV ceftriaxone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SC ceftriaxone (with or without rHuPH20)
Number of subjects: 54
Study: 18422695

Group type: EXPERIMENTAL
Intervention: 0.2% CHX mouthwash with anti discoloration system (ADS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.2% CHX mouthwash without anti discoloration system (ADS)
Number of subjects: 48
Study: 15655130

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lipoic acid 300 mg/d
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d and Lipoic acid 300 mg/d
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 12805489

Group type: EXPERIMENTAL
Intervention: UK‐279,276 (1.0 mg/kg)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: UK‐279,276 (1.5 mg/kg)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: UK‐279,276 (0.06, 0.1, 0.2, 0.5, 1.0, 1.5 mg/kg)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: UK‐279,276
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: UK‐279,276 (1.0 and 1.5 mg/kg)
Number of subjects: 176
Study: 11191952

Group type: EXPERIMENTAL
Intervention: Single booster vaccination (day 0)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Two booster vaccinations (day 0, 28)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Both interventions (single and two boosters)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 185
Study: 8606643

Group type: EXPERIMENTAL
Intervention: Combined CRF/AVP test (100 micrograms CRF plus 0.3 IU AVP IV)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Standardized stress test (puzzles and mental arithmetic)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control saline test
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Stress test
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subjective emotional involvement during stressful tasks
Number of subjects: 3
Study: 1610575

Group type: EXPERIMENTAL
Intervention: Early anesthesia evaluation (1 to 7 days preoperative)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Day-of-surgery evaluation
Number of subjects: 63
Study: 6208468

Group type: EXPERIMENTAL
Intervention: Cyclocytidine (Cyclo‐C)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cytosine arabinoside (Ara‐C) given every 12 hr
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with cyclophosphamide combined with Ara‐C
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with Cyclo‐C
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Addition of VP‐16 and CCNU to maintenance therapy
Number of subjects: 130
Study: 31629944

Group type: EXPERIMENTAL
Intervention: Pre/interconception health intervention delivered during pediatric primary care
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care comparison group
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Pre/interconception health intervention
Number of subjects: 415
Study: 31233859

Group type: EXPERIMENTAL
Intervention: Kids SIPsmartER program (6-month school-based behavior and health literacy program)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Kids SIPsmartER program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control schools (not receiving Kids SIPsmartER)
Number of subjects: 12
Study: 28145073

Group type: EXPERIMENTAL
Intervention: Dermalax implant plus™
Number of subjects: 52

Group type: COMPARATOR
Intervention: Restylane Sub‐Q®
Number of subjects: 52
Study: 26269089

Group type: EXPERIMENTAL
Intervention: CAF + CGF (test; 60 defects)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CAF (control; 59 defects)
Number of subjects: 20
Study: 23863816

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pressure support (PSinit)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pressure support (PSbest)
Number of subjects: 6
Study: 21610420

Group type: EXPERIMENTAL
Intervention: Pseudoaneurysm screening (PSA-S) for grades IV and V injuries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial angioembolization (IE) for grade IV and V injuries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis prophylaxis (DVT-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation only for grades I and II injuries
Number of subjects: 0
Study: 19705681

Group type: EXPERIMENTAL
Intervention: Integrated ICPS drug and employment counseling (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: ICPS drug counseling control condition (n = 11)
Number of subjects: 23
Study: 17012300

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg intravenous infusion over 30 min)
Number of subjects: 104
Study: 12431972

Group type: EXPERIMENTAL
Intervention: Study agent (cytostatic agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9927265

Group type: EXPERIMENTAL
Intervention: Low-dose vancomycin (500 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose vancomycin (2 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole (1 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 8745203

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin and sulfonylurea
Number of subjects: 27
Study: 2040035

Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg/m2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Epirubicin 135 mg/m2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 78
Study: 7004720

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (10 mg daily) for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (10 mg daily) for 10 weeks
Number of subjects: 0
Study: 6882732

Group type: EXPERIMENTAL
Intervention: Malted cocoa drink fortified with FePO4 and ascorbic acid (1 mg/g powder)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malted cocoa drink fortified with FePO4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malted cocoa drink fortified with FeSO4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0
Study: 31069575

Group type: EXPERIMENTAL
Intervention: Pirfenidone for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 0
Study: 29490721

Group type: EXPERIMENTAL
Intervention: Oligofructose-supplemented granola bar (OF-Bar)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control granola bar (Co-Bar)
Number of subjects: 55
Study: 26758281

Group type: EXPERIMENTAL
Intervention: Ebselen (3600 mg over 24 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (identical to ebselen)
Number of subjects: 20
Study: 24574355

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12537
Study: 22009510

Group type: EXPERIMENTAL
Intervention: 550 mg oral naproxen sodium plus active TENS
Number of subjects: 65

Group type: COMPARATOR
Intervention: 550 mg oral naproxen sodium plus placebo TENS
Number of subjects: 65
Study: 20493632

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 18581586

Group type: EXPERIMENTAL
Intervention: 40 mg of parecoxib
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 g of proparacetamol
Number of subjects: 50
Study: 15781816

Group type: EXPERIMENTAL
Intervention: Gray Matter Fraction (GMF) in RRMS patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: White Matter Fraction (WMF) in RRMS patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: White Matter Fraction (WMF) in RRMS patients with largest decline in Gd volume
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: White Matter Fraction (WMF) in RRMS patients with increased Gd-enhancing lesions
Number of subjects: 21
Study: 12902996

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy participants (Control)
Number of subjects: 19
Study: 10500010

Group type: EXPERIMENTAL
Intervention: High-fat test breakfasts (4 different breakfasts)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Low-fat control breakfast
Number of subjects: 91
Study: 8628042

Group type: EXPERIMENTAL
Intervention: 12-item short-form (SF-12)
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: 12-item Physical Component Summary
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: 12-item Mental Component Summary
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: 12-item short-form
Number of subjects: 2333
Study: 1909444

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fluvoxamine
Number of subjects: 0
Study: 7168548

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 33

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 33
Study: 30774288

Group type: EXPERIMENTAL
Intervention: Pressure injury prevention intervention program
Number of subjects: 50
Study: 29382298

Group type: EXPERIMENTAL
Intervention: 8 weeks of high-intensity treadmill training embedded in self-management education
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual physiotherapy gait training
Number of subjects: 128
Study: 26739742

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 120
Study: 24685996

Group type: EXPERIMENTAL
Intervention: Interdisciplinary team of a nurse, occupational therapist, and handyman
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control of sedentary activities of choice
Number of subjects: 0
Study: 22108444

Group type: EXPERIMENTAL
Intervention: 80mg simvastatin
Number of subjects: 650

Group type: COMPARATOR
Intervention: 40mg simvastatin
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study: 20179234

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 912

Group type: COMPARATOR
Intervention: No adjuvant endocrine treatment
Number of subjects: 912
Study: 17010685

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 2617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study: 15983347

Group type: EXPERIMENTAL
Intervention: Community-based intervention (details not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care control group (details not specified)
Number of subjects: 0
Study: 12172717

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam in 25 ml normal saline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 25 ml normal saline
Number of subjects: 42

Group type: COMPARATOR
Intervention: 25 ml normal saline (control)
Number of subjects: 42
Study: 10199760

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lipid infusion (10% at 150 mL/h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7493372

Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 million units daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no IFN-alpha treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 0
Study: 2097909

Group type: EXPERIMENTAL
Intervention: Topical benzocaine 20%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical benzocaine 20% vs Topical lidocaine 5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical anesthetics (benzocaine 20% and lidocaine 5%)
Number of subjects: 0
Study: 6162314

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study: 30807516

Group type: EXPERIMENTAL
Intervention: Intravitreal 0.5‐mg ranibizumab
Number of subjects: 25

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 25
Study: 28800951

Group type: EXPERIMENTAL
Intervention: High-concentration contrast media (HCCM) injection protocol with low tube current (effective mAs reduced by a factor of 0.6, HCCM 400 mgI/mL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low concentration contrast medium (300 mgI/mL) with automatic mAs
Number of subjects: 81
Study: 26059274

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin/carboplatin (Arm A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Docetaxel alone (Arm B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 23787155

Group type: EXPERIMENTAL
Intervention: High Hb group (target Hb 11.0 ≤ target Hb ≤ 13.0 g/dL with darbepoetin alfa)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Low Hb group (target Hb 9.0 ≤ target Hb ≤ 11.0 g/dL with recombinant human erythropoietin)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: High Hb group
Number of subjects: 206
Study: 21636031

Group type: EXPERIMENTAL
Intervention: Bivalirudin (switch group)
Number of subjects: 2357

Group type: COMPARATOR
Intervention: UFH plus glycoprotein IIb/IIIa inhibitor (control group)
Number of subjects: 2357
Study: 19855038

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention by trained family physicians
Number of subjects: 65

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 65
Study: 16540812

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 14743544

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (Vit E group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 10877738

Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine
Number of subjects: 33
Study: 8888297

Group type: EXPERIMENTAL
Intervention: Body tilted 45 degrees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Body erect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body tilted 45 degrees after extensive practice
Number of subjects: 0
Study: 1544739

Group type: EXPERIMENTAL
Intervention: 450 mg caffeine with exercise (running for 30 min at 75% of maximum heart rate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 450 mg caffeine without exercise
Number of subjects: 9
Study: 3916264

Group type: EXPERIMENTAL
Intervention: Caffeine fading
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Caffeine fading plus relaxation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Self-initiated treatment
Number of subjects: 27
Study: 30272459

Group type: EXPERIMENTAL
Intervention: Mailed letter incorporating principles of motivational interviewing and addressing outcome expectancies plus a telephone reminder call
Number of subjects: 69

Group type: COMPARATOR
Intervention: Telephone reminder call only
Number of subjects: 69
Study: 29756790

Group type: EXPERIMENTAL
Intervention: PATd/TAU
Number of subjects: 79

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 79
Study: 27312538

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT) cream containing oestradiol 50mcg and norethisterone acetate 140mcg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Targeted intervention exercise
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 116
Study: 26321237

Group type: EXPERIMENTAL
Intervention: ATP-guided PVI
Number of subjects: 2113

Group type: COMPARATOR
Intervention: Conventional PVI
Number of subjects: 2113
Study: 23493565

Group type: EXPERIMENTAL
Intervention: Endoscopy training on a validated colonoscopy simulator protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laparoscopy training on a validated laparoscopy simulator curriculum
Number of subjects: 30

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 30
Study: 21874637

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 100
Study: 19170463

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg, fixed‐flexible dose)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 16791541

Group type: EXPERIMENTAL
Intervention: Once-daily modified-release MPH (EqXL) at doses of 20, 40, or 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily immediate-release methylphenidate (MPH-IR) at doses of 10, 20, or 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15531675

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 16
Study: 10834775

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.25% with epinephrine (20 microg/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.25% without epinephrine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine with epinephrine
Number of subjects: 28
Study: 9314869

Group type: EXPERIMENTAL
Intervention: Two-drug regimen (doxorubicin 25 mg/m2 on days 1-3 and cisplatin 100 mg/m2 on day 1 for six cycles over 18 weeks)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Multi-drug regimen (preoperatively vincristine, high-dose methotrexate, and doxorubicin; postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, and cisplatin over 44 weeks)
Number of subjects: 407
Study: 7984314

Group type: EXPERIMENTAL
Intervention: 5% isoflurane in air (group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 3% isoflurane and 60% N2O (group 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 2566790

Group type: EXPERIMENTAL
Intervention: Prednisolone plus melarsoprol
Number of subjects: 598

Group type: COMPARATOR
Intervention: Melarsoprol only
Number of subjects: 598
Study: 1824

Group type: EXPERIMENTAL
Intervention: 30 mg d-amphetamine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 30 mg d-amphetamine with lithium carbonate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 30 mg l-amphetamine with lithium carbonate
Number of subjects: 9
Study: 31335733

Group type: EXPERIMENTAL
Intervention: Mechanical power
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: TGF‐β1
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CTGF
Number of subjects: 95
Study: 28482692

Group type: EXPERIMENTAL
Intervention: Baseline heart rate (per 5 bpm increase)
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: Baseline heart rate (per 5 bpm increase) without β-blockers
Number of subjects: 2705
Study: 25845224

Group type: EXPERIMENTAL
Intervention: Acupoint-injection of BCG polysaccharide nucleic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular-injection of BCG polysaccharide nucleic acid
Number of subjects: 60
Study: 25831701

Group type: EXPERIMENTAL
Intervention: Autotransfusion of washed erythrocytes from placental/umbilical cord blood
Number of subjects: 122

Group type: COMPARATOR
Intervention: Donor erythrocytes
Number of subjects: 122
Study: 22459649

Group type: EXPERIMENTAL
Intervention: Volumetric Modulated Arc Therapy (RapidArc)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dynamic IMRT (d-IMRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3D Conformal Radiotherapy (3D-CRT)
Number of subjects: 20
Study: 20718625

Group type: EXPERIMENTAL
Intervention: Quitters (self-reported cigarette abstinence confirmed with exhaled carbon monoxide [CO] <or=8 ppm at 3 and 16 months after quit date)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Continued smokers
Number of subjects: 119
Study: 18684382

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention after global geriatric assessment (GGA)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention after GGA
Number of subjects: 620
Study: 15526012

Group type: EXPERIMENTAL
Intervention: rHuEpo (300 units per kg per dose, subcutaneous, for 10 days) plus oral iron
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral iron alone
Number of subjects: 60